Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19381874 | 0.82 | ALDH1A1 (0.39) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL7933658 | 0.81 | CHRNB2 (0.37) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL11462510 | 0.81 | CHRNB2 (0.41) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL13351707 | 0.78 | KCNH2 (0.47) | KCNH2CHRNB2SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL8034198 | 0.78 | MMP2 (0.39) | KCNH2CHRNB2SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL28117469 | 0.78 | CHRNB2 (0.42) | KCNH2OPRM1OPRL1OPRK1CHRNB2 | |
| SCHEMBL5166696 | 0.76 | TAAR1 (0.40) | KCNH2OPRM1OPRL1OPRK1ALDH1A1 | |
| SCHEMBL25362375 | 0.76 | KCNH2 (0.46) | KCNH2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13473 | 0.76 | TAAR1 (0.50) | KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL2010666 | 0.76 | KCNH2 (0.46) | KCNH2OPRK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111454689-B | Heat-conducting adhesive with high glass transition temperature and preparation method thereof | 武汉长盈鑫科技有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-111454689-A | Heat-conducting adhesive with high glass transition temperature and preparation method thereof | 武汉长盈鑫科技有限公司 | 2020-07-28 | — | — | CN | claimed |
| US-20230002650-A1 | BIOCOMPATIBLE ADHESIVE | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2023-01-05 | — | — | US | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-109641898-B | 5, 7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases | 辉瑞公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-111454689-B | Heat-conducting adhesive with high glass transition temperature and preparation method thereof | 武汉长盈鑫科技有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2020-08-27 | — | — | US | disclosed |
| CN-111454689-A | Heat-conducting adhesive with high glass transition temperature and preparation method thereof | 武汉长盈鑫科技有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| EP-1902829-B1 | THREE-DIMENSIONAL SHAPED ITEM WITH SMOOTHED MOLDING END FACE | CMET INC (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| WO-2011044187-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-1902829-A1 | THREE-DIMENSIONAL SHAPED ITEM WITH SMOOTHED MOLDING END FACE | Cmet Inc. (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | KCNH2 4883/4885OPRM1 3750/4885OPRL1 3231/4885 |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | KCNH2 4883/4885OPRM1 3750/4885OPRL1 3231/4885 |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | KCNH2 2169/4885OPRM1 3447/4885OPRL1 2189/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | KCNH2 2169/4885OPRM1 3447/4885OPRL1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.